UnitedHealthcare and Optum Act to Support People Affected by Hurricanes Madeline and Lester

UnitedHealth Group | August 31, 2016

UnitedHealthcare and Optum, the health benefits and services companies of UnitedHealth Group (NYSE: UNH), are taking immediate action to help people affected by Hurricane Madeline and Hurricane Lester, which are expected to hit Hawaii over the next few days. This includes a free emotional-support line to help people in the affected communities, and assisting health plan participants who may be affected and need to make alternate arrangements to ensure continuity of care.

Spotlight

This workshop presented innovative mobile technology solutions from South Asia to improve access to affordable health care, in a comparative context with solutions other regions in the global south. Tarun Khanna, Director of the South Asia Institute & Jorge Paulo Lemann Professor, Harvard Business Schoo Nathan Sigworth, Director, PharmaSecure Jill Shah, Associate Consultant, Vera Solutions Facilitator: Satchit Balsari, FXB Center for Health and Human Rights; Cornell Weill Medical Center


Other News
HEALTH TECHNOLOGY

HONEYWELL AND NARAYANA HEALTH PARTNER TO EXPLORE CO-CREATION OF HEALTHCARE TECHNOLOGIES

Honeywell | May 27, 2022

Honeywell announced the signing of a non-binding memorandum of understanding (MoU) with Narayana Hrudayalaya Limited to identify, assess and collaborate on opportunities for the latter's digital transformation journey. This will enable Narayana Health to offer technology-driven, affordable and accessible healthcare for all. The MoU is subject to definitive agreements to be executed between Honeywell and Narayana Health. "These are times of great promise and even greater opportunities in healthcare innovation. At Honeywell, we recognize this and have pivoted towards the development of technologies that will shape the future of healthcare delivery. The MoU with Narayana Health – one of India's foremost healthcare service providers – offers us an opportunity to create a strategic technology development roadmap that will eventually transform India's healthcare industry," said Suresh Venkatarayalu, Chief Technology Officer, Honeywell. "Sensors and digital technology will disrupt health care delivery. Narayana Healthcare is delighted to work with Honeywell to develop digital technologies for making health care safer, more accessible, and more affordable," said Dr. Devi Prasad Shetty, Chairman and Executive Director, Narayana Healthcare. Honeywell's Advanced Sensing Technologies (AST) healthcare business builds on the company's global leadership in sensors to offer devices and software for hospitals, clinics and elderly care facilities to improve communication, collaboration and coordination of clinical care. "The pandemic made it abundantly clear that healthcare organizations need technology that can be seamlessly integrated into existing systems and processes to streamline error prone tasks, enhance patient experience, and improve organizational agility," said Robert Robinson, Vice President and General Manager, Advanced Sensing Technologies Healthcare, Honeywell. Based on the terms of the MoU, Honeywell and Narayana Health will work towards co-innovation and introduction of new products, establish technology development centers, co-create joint capabilities in technology development and research, and undertake the development of fire safety codecs that ensure an end-to-end life safety system to make hospitals safer. As a technology partner, Honeywell will also help enhance and optimize Narayana Health's digital processes and offer training to its employees. The healthcare industry is continuously evolving to keep up with increasing regulatory pressures, while maintaining an environment where patients and staff feel safe. COVID-19 highlighted the need for bringing efficiencies in healthcare delivery to enable fewer personnel to do more onsite. The growth in telemedicine also opened newer avenues for hospitals to manage patient care. Healthcare providers often struggle with developing the right approach to stay ahead of these changes. To help meet some of these challenges, last year Honeywell launched its Real-Time Health Monitoring System (RTHMS). This is a smart edge-to-cloud communication platform for remote and real-time patient monitoring that acts as a bridge between caregiver and patient. This offering integrates hardware and software to improve care delivery, enhance healthcare worker productivity, and enable process efficiency. By digitizing and automating critical tasks, RTHMS can reduce hospital administrative tasks by 35%.1 "Narayana Healthcare has made remarkable progress in using technology to improve clinical outcomes and increase healthcare delivery efficiency. Honeywell's sensor-based applications will complement our efforts in real-time patient monitoring and fire safety, raising the bar for others to meet," Dr. Emmanuel Rupert, Managing Director and Group Chief Executive Officer, Narayana Hrudayalaya Limited Honeywell has a robust portfolio of healthcare technologies – from a patient's first visit, to diagnosis, and returning home from care, Honeywell has the technologies to help healthcare providers increase productivity, efficiency, and shape the future of their organizations. About Honeywell Honeywell is a Fortune 100 technology company that delivers industry-specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally. Our technologies help aircraft, buildings, manufacturing plants, supply chains, and workers become more connected to make our world smarter, safer, and more sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom.

Read More

HEALTH TECHNOLOGY

Ivenix to be Acquired by Fresenius Kabi

Ivenix | April 01, 2022

Ivenix, Inc. announced that it has entered into a definitive agreement to be acquired by Fresenius Kabi, a global health care leader specializing in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Ivenix’s advanced infusion system combined with Fresenius Kabi’s intravenous fluids and infusion therapy offerings will bring a comprehensive portfolio of infusion products to U.S. hospitals. The purchase price will be a combination of US$240 million upfront payment and milestone payments linked to achievements of commercial and operating targets. The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close by mid-2022. The transaction is designed to Create a comprehensive portfolio that joins the industry’s most advanced infusion pump technology with the newest source of intravenous fluids, infusion supplies and accessories. Accelerate operational and commercial growth and scale providing a platform for rapid expansion. Build on a shared culture of exceptional customer service. Establish Fresenius Kabi as a leader in the approximately $5 billion infusion segment. This pivotal transaction will accelerate innovation, expand our combined infusion therapy portfolio and enhance our infusion capabilities, resulting in improved medication safety and operational efficiency. “We’re very pleased to partner with Fresenius Kabi, a leading global health care company. Together, we intend to transform the standard of care for North American health care providers and patients by providing the highest level of safe and effective integrated infusion care,” Jorgen B. Hansen, Ivenix’s Chief Executive Officer The Ivenix Infusion System includes a large-volume infusion pump with administration sets, infusion management tools, and analytics to inform care and advance efficiency. Ivenix centered the system around the patient and clinician and designed it to reduce infusion-related errors and drive down the total cost of ownership. After receiving U.S. Food and Drug Administration (FDA) clearance, Ivenix successfully launched the infusion system in 2021. “Combining Ivenix’s expertise in pump technology and software with our infrastructure, portfolio, and presence in hospital settings represents an ideal opportunity. We intend to scale the launch of Ivenix’s next-generation infusion system while driving growth opportunities in the United States. With today’s announcement, Fresenius Kabi expects to create a leading, comprehensive infusion therapy offering,” said Michael Sen, President and CEO, Fresenius Kabi. About Ivenix Ivenix, Inc. is a medical technology company with a vision to eliminate infusion-related patient harm. The company was founded to develop innovative solutions that transform infusion delivery. Ivenix designed an infusion system from the ground up to streamline medication delivery and bring infusion technology into the digital age. The Ivenix Infusion System includes a large-volume infusion pump supported by a robust infusion management system designed to set new standards in simplicity, intelligence, and reliability. For more information, visit ivenix.com. The Ivenix Infusion System is cleared by the FDA.

Read More

HEALTH TECHNOLOGY

L2Mtech GmbH Receives CE Mark Approval on 6(SIX) products for Cardiovascular and Endovascular Applications

L2Mtech | February 17, 2021

CE Mark Approval for LimusTrack™, Sirolimus Eluting Coronary Stent System for Cardiovascular Applications. CE Mark Approval for LomiFlow™, Paclitaxel Drug Eluting Balloon for Cardiovascular Applications CE Mark Approval for PearlFlow™, Paclitaxel Drug Elutin Balloon for Endovascular Applications CE Mark Approval for PearlFlow NS™, Self Expandable Nitinol Stent System for Endovascular Applications CE Mark Approval for FlexiTrack 018™, Peripheral Balloon Catheter for Endovascular Applications CE Mark Approval for FlexiTrack 035™, Peripheral Balloon Catheter for Endovascular Applications Bonn, Germany – L2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products: LimusTrack™ : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the treatment of coronary artery disease, de novo lesions, restenosis lesions. LomiFlow™ : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease, small vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases. PearlFlow™ : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease, PTA, dilatation of stenotic segments or lesions in peripheral arteries. PearlFlow NS™ : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial disease, de novo lesions, lesions in femoropopliteal arteries. FlexiTrack 018™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in femoral, popliteal, tibial arteries. FlexiTrack 035™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in the SFA, femoral arteries. L2Mtech GmbH Founder and CEO Lalit Mamtani said ‘‘We are very excited to have been awarded our first CE Mark on six products, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to the efficacy and safety of our innovative technology products for Cardiovascular and Endovascular applications.“ We now prepare to commercially launch the products in all markets where the CE Mark is recognized. With introduction of our innovative technology products in markets, we will be able to expand treatment options for the benefit of many millions of patients with coronary and peripheral artery disease around the world. About L2Mtech Founded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company headquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture and commercialization of medical devices that are used by healthcare establishments globally. L2MTech will provide interventional physicians with innovative vascular devices including Drug Eluting Balloon manufactured in Europe.Our Core mission is to build a product portfolio focused on minimally invasive treatment for patients with cardiovascular,endovascular and vascular artery disease. For further information, please visit : L2MTech.de Media Contact: L2Mtech GmbH admin@L2Mtech.de +49 228 94730761

Read More

FUTURE OF HEALTHCARE

Althea Expands Its Growing Broadband Coverage Area to Tacoma WA

Althea | March 26, 2022

Althea is proud to announce Tacoma, WA is the latest addition to its growing broadband coverage area, with installations and infrastructure investment focused in the Hilltop neighborhood. Founded in 2017, Althea’s mission is rooted in the belief that affordable broadband connectivity is a fundamental right for all people that strengthens communities, economic growth, educational opportunities, and healthcare access. Althea is a distributed Internet Service Provider which works together with local communities and network operators to provide sustainable high speed and low cost broadband access. This is made possible by Althea’s unique technology, infrastructure, and routing protocol. Althea’s routing protocol allows the service and accounting layers of the ISP to be almost entirely automated, and maximizes bandwidth utilization (i.e. delivers lower latency and higher speeds than one would typically experience from a given network connection, when compared to a traditional ISP routing protocol). This technology negates the need for contracts, late fees, and other drawbacks of traditional internet delivery. The mesh topology used to connect users also allows individuals to host infrastructure themselves, growing the network, and earning revenue share for doing so. This keeps value in the community, encourages community involvement, maintains low costs, and creates an ever more resilient network architecture. Althea uses a unique pay-as-you-go payment model, making it easy for users to manage costs. Additionally, each user has access to the always-on free tier, guaranteeing they will have access to no-cost basic internet, regardless of their financial situation. Unlike traditional ISPs, Althea’s technology does not artificially throttle bandwidth or utilize speed tiers either, so users always get the maximum speed their equipment is capable of delivering. Althea users in Tacoma can expect speeds around 100 Mbps and pay, on average, around $25/month. “Many people don’t have access to the internet, not because of availability, but costs and other barriers keep them from this vital resource.We believe internet access is a human right, which is why we provide an always-on, free tier of internet.” Deborah Simpier, Althea CEO and co-founder Hilltop, Tacoma was also one of the first proof-of-concept networks for Althea, partnering in 2020 with Tacoma Cooperative Network and the University of Washington to build and test community led LTE networks. Through this work in Open5GS, Althea developed KeyLTE, which is an embedded EPC inside an Althea home router, which provides flexibility to build and grow LTE/5G networks anywhere, quickly and affordably.

Read More

Spotlight

This workshop presented innovative mobile technology solutions from South Asia to improve access to affordable health care, in a comparative context with solutions other regions in the global south. Tarun Khanna, Director of the South Asia Institute & Jorge Paulo Lemann Professor, Harvard Business Schoo Nathan Sigworth, Director, PharmaSecure Jill Shah, Associate Consultant, Vera Solutions Facilitator: Satchit Balsari, FXB Center for Health and Human Rights; Cornell Weill Medical Center

Resources